Cencora, Inc 8-K, filed Jan 3, 2023
Cencora, Inc. (COR)
About this 8-K
Cencora, Inc filed this 8-K on January 3, 2023, reporting on events of January 1, 2023.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
Commission File Number:
(State or other jurisdiction of |
(I.R.S. Employer | |
| incorporation or organization) | Identification No.) | |
|
|
| |
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
Effective January 1, 2023, AmerisourceBergen Corporation (the “Company”) completed the previously announced acquisition of PharmaLex Holding GmbH. A copy of the Company’s press release announcing the closing is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number | Description of Exhibit | ||
| 99.1 | News Release of AmerisourceBergen Corporation, dated January 3, 2023. | ||
| 104 | Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERISOURCEBERGEN CORPORATION | |||
| Date: | January 3, 2023 | By: | /s/ James F. Cleary |
| Name: | James F. Cleary | ||
| Title: | Executive Vice President and Chief Financial Officer | ||
Exhibit 99.1
| PRESS RELEASE | |
![]() |
|
| AmerisourceBergen Corporation | |
| 1 West First Avenue | |
| Conshohocken, PA 19428 |
AmerisourceBergen COMPLETES ACQUISITION OF PHARMALEX
Acquisition advances role as a partner of choice for biopharmaceutical companies by enhancing global portfolio of specialty services
CONSHOHOCKEN, PA, January 3, 2023 — AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.
The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen’s role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.
| Contacts: | Investors: |
| Bennett S. Murphy | |
| 610-727-3693 | |
| bmurphy@amerisourcebergen.com | |
| Media: | |
| Lauren Esposito | |
| 215-460-6981 | |
| lesposito@amerisourcebergen.com |
1
